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EDITORIAL
Clinical trials of endothelin antagonists in heart failure:
publication is good for the public health
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The failure of endothelin antagonists to show benefit in heart
failure cannot be understood until all the clinical trials are fully
published
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E
ndothelin-1 (ET-1) activates endothelin A
(ETA) and B (ETB) receptors on vascular
smooth muscle cells, resulting in profound
vasoconstriction and cellular proliferation.1–3 By
contrast, endothelial cell ETB receptors release
nitric oxide and prostacyclin, which are antimitotic
and mediate vasodilatation.4 The relative expres-
sion of vascular smooth muscle ETB to endothelial
ETB receptors varies in different vascular beds and
with cardiovascular disease.5 Endothelial cell ETB
receptors are also responsible for clearance of ET-1
from the circulation, and thus raised plasma ET-1
concentrations act as an index of ETB blockade.
6 7
Renal ETB receptors may contribute to natriuresis.
4
Drugs have been developed that are active against
ETA receptors (ETA selective antagonists) or
against both ETA and ETB receptors (mixed
antagonists).
ROLE OF ET-1 IN CHRONIC HEART FAILURE
Like several other neurohumoral systems, the
endothelin system is activated in chronic heart
failure (CHF). In experimental heart failure,
treatment with either mixed or ETA-selective
antagonists considerably ameliorated left ventri-
cular dysfunction, prevented ventricular remodel-
ling and prolonged survival after coronary artery
ligation.8 Plasma ET-1 concentrations in patients
with CHF correlate with both morbidity and
mortality, prompting investigators to pursue the
therapeutic potential of endothelin blockade in
CHF,8 and short-term haemodynamic studies were
promising. Two weeks of oral treatment with the
mixed endothelin antagonist, bosentan, reduced
pulmonary vascular resistance by around 40% and
systemic vascular resistance by 30%, without
affecting heart rate.9 Similarly favourable results
were found using the ETA selective antagonist
darusentan, in the Haemodynamic and
Neurohumoral Effects of Selective Endothelin A
Receptor Blockade in Chronic Heart Failure
(HEAT) Study.10
In light of these, and other, encouraging results,
clinical trials were undertaken. In the Research on
Endothelin Antagonists in Chronic Heart Failure
Study,11 the long-term effects of the mixed
endothelin antagonist bosentan (n = 244) versus
placebo (n = 126) in patients with New York Heart
Association (NYHA) class IIIB/IV CHF were
assessed. This trial was halted prematurely because
of increased incidence of raised liver transaminase
levels. Nevertheless, patients who had been receiv-
ing treatment over a 6-month period showed a
trend towards a reduced risk of CHF-related
mortality and morbidity. The possibility that
long-term bosentan treatment, at a lower dose,
would improve the clinical course of patients with
CHF was evaluated in two companion large-scale
clinical trials, Endothelin Antagonist Bosentan for
Lowering Cardiac Events in Heart Failure 1 and 2,
which were conducted in the US and Europe,
respectively. Patients with NYHA class IIIB/IV CHF
were given bosentan (n = 805) or placebo
(n = 808) in addition to standard treatment.
However, the study failed to show that bosentan
reduced either morbidity or mortality.12 Treatment
of patients (class II/III CHF) with another mixed
antagonist enrasentan (n = 212) or placebo
(n = 157) failed to show benefit in a composite
end point including NYHA class, hospitalisation
rate and global assessment; it rather showed a
trend in favour of placebo (Enrasentan
Cooperative Randomized Evaluation Study).13
None of the clinical trials described above have
been fully published. The data required to under-
stand the effects of treatment with endothelin
antagonists in CHF are not in the public domain
and cannot be subjected to independent peer
review. Hence, there has been no opportunity to
look across the trials to learn potentially important
lessons from them, including whether there may
be ways in which patients with CHF might benefit
from endothelin antagonists.
ENDOTHELIN ANTAGONISTS: NO EFFECT
ON END SYSTOLIC VOLUME
In the Endothelin A Receptor Antagonist Trial in
Heart Failure (EARTH) Study, patients with NYHA
class II-IV CHF, already receiving standard treat-
ment, were randomised to treatment either with
darusentan (n = 532) or with placebo (n = 110)
over 24 weeks.14 The primary end point was the
change in left ventricular end systolic volume over
the 24 weeks of the study measured by magnetic
resonance imaging, rather than long-term mortal-
ity, a more conventional end point in CHF trials.
The effect of darusentan on left ventricular end
systolic volume was no different from that of
placebo. Furthermore, during the 6-month-long
Abbreviations: CHF, chronic heart failure; EARTH,
Endothelin A Receptor Antagonist Trial in Heart Failure;
HEAT, Haemodynamic and Neurohumoral Effects of
Selective Endothelin A Receptor Blockade in Chronic Heart
Failure; NYHA, New York Heart Association
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study, no difference was seen in terms of mortality or the
progression of CHF. Perhaps importantly, as had previously
been shown in the HEAT Study,10 plasma levels of endothelin-1
increased dose dependently in all groups receiving darusentan
(p = 0.0028), suggesting that the doses were not ETA selective.
WHY DID THE CLINICAL TRIALS YIELD NEGATIVE
RESULTS?
The promise of clinical benefit from endothelin antagonists in
CHF, on the basis of the results of initial preclinical and human
haemodynamic studies, has clearly not been fulfilled by the
results of large clinical trials, for which there are several
possible explanations.
1. Although with some drugs, such as angiotensin-convert-
ing enzyme (ACE) inhibitors, short-term haemodynamic
studies showing acute improvement can translate into
reduced morbidity and mortality in longer-term clinical
trials,15 this is not a reliable surrogate for all therapeutic
agents in CHF.16
2. Despite early studies using endothelin antagonists show-
ing improvements in haemodynamic variables, and indeed
in mortality in animal models of CHF post-myocardial
infarction,17 18 most likely owing to an effect on cardiac
remodelling, a recent meta-analysis of the many preclini-
cal studies indicates that endothelin antagonists have no
net beneficial effect on mortality.19 Indeed, early admin-
istration of endothelin antagonists after experimental
myocardial infarction may increase mortality, most likely
due to a remodelling-related increase in cardiac dimen-
sions.20 21
3. Endothelin blockade might have been successful if it had
been introduced before the incremental introduction of
ACE inhibitors, b-blockers and spironolactone, which are
now established as ‘‘standard’’ CHF treatment. Once
several neurohumoral systems are blocked, there may be
little room for additional benefit, especially if the
beneficial actions of endothelin antagonists overlap with
those of pre-existing drugs.
4. There may only be specific subgroups, within the total
population of patients with CHF, in whom endothelin
blockade is beneficial. These may not have been recog-
nised from the clinical trials so far. Endothelin antagonists
are known to reduce pulmonary artery pressures in both
patients with primary pulmonary hypertension and
secondary pulmonary hypertension, due to left ventricular
dysfunction.22 Thus, it is possible that patients with CHF
with raised pulmonary arterial pressures might benefit
from treatment with endothelin antagonists.
5. In contrast with the CHF clinical trials associated with
either ACE inhibitors or angiotensin receptor antago-
nists,23 treatment with darusentan in both the HEAT10 and
the EARTH14 studies did not reduce norepinephrine
plasma concentrations, thus suggesting that endothelin
antagonism, unlike blockade of the renin–angiotensin
system, does not have an inhibitory effect on the
sympathetic nervous system in CHF.
6. Given the darusentan data, the benefits of endothelin
blockade in CHF may derive from ETA, but not ETB
blockade, which causes deleterious effects including
increased plasma ET-1 levels.24 In patients with chronic
renal failure and hypertension, the ETA antagonist, BQ-
123, reduced renal vascular resistance and induced
natriuresis, effects not seen with mixed ETA/B blockade.
25
Hence, in patients with CHF, selective ETA antagonism
might be more likely than mixed ETA/B blockade to avoid
fluid retention. In the coronary microcirculation of
patients with ischaemic heart disease, endothelial dys-
function, a known independent risk factor for the
development of cardiovascular disease,26 was improved
after ETA,
27 but not with combined ETA/B blockade.
28
All endothelin antagonists currently under clinical develop-
ment show greater affinity towards the ETA than towards ETB
receptor (table 1), but are generally classified as ETA receptor
antagonists if they show more than 100-fold selectivity for the
ETA over the ETB receptor.
29 However, selectivity is dependent
on dose, and higher doses of these agents can result in ETB
receptor blockade,30 causing increased ET-1 plasma levels. By
contrast, when truly ETA selective (.20006) antagonists are
used, no significant increase in plasma ET-1 is seen.7 24 31 32
Such data are not dependent on standardised assays, and are
given only to allow broad comparison between different
antagonists.
The first three clinical trials of endothelin antagonists in CHF
(Research on Endothelin Antagonists in Chronic Heart Failure,
Endothelin Antagonist Bosentan for Lowering Cardiac Events in
Heart Failure, Enrasentan Cooperative Randomized Evaluation)
have not been published, hence their detailed results, including
the effect of drug treatment on plasma ET-1 levels, are not
known. However, treatment with darusentan, the most ETA
selective of the agents so far studied in CHF trials, dose
dependently increased plasma ET-1 levels in the HEAT10 and
EARTH studies.14 Thus, probably none of the endothelin
antagonists studied so far, at the doses used in the clinical trials,
have tested the outcomes with an ETA-selective approach in CHF.
ENDOTHELIN ANTAGONISTS IN CHF: THE NEXT
STEPS
Although the International Committee of Medical Journal
Editors will now consider publishing only trials that have been
centrally registered before the first patient was recruited,41 this
does not apply retrospectively. Of the clinical trials of
endothelin antagonists in CHF, only the EARTH Study has
been published. Although we acknowledge that there is little
commercial pressure to publish negative studies (and there may
be little new to uncover), until the data from these trials are
made publicly available, full independent analysis and inter-
pretation of the results, from which patients might serve to
benefit, will not be possible. We, like others,42 would argue that
it is an ethical imperative that trial coordinators should honour
their responsibility to the patients that they recruit for clinical
studies not only by registering their trials but also by publishing
their results.43
Although the EARTH Study investigated the effect of
darusentan, an agent with modest selectivity for the ETA
receptor in CHF, at the doses used in this trial, it seems to have
Table 1 Drug codes, names and selectivity for the ETA
receptor for a range of endothelin antagonists used in
preclinical and clinical studies
Drug code Drug name ETA selectivity Ref
J-104132 NA X 5 Nishikibe et al33
RO-470203 Bosentan X 20 Clozel et al34
RO-610612 Tezosentan X 30 Clozel et al35
SB-217242 Enrasentan X 110 Ohlstein et al36
LU-135252 Darusentan X 130 Munter et al37
A-627; A-
127722
Atrasentan X 1860 Opgenorth et al38
BQ-123 NA X 2500 Ishikawa et al39
TBC-11251 Sitaxsentan X 6500 Wu et al40
ZD-4054 NA .X 10000 Morris et al32
NA, not available.
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had considerable activity at the ETB receptor. Truly, ETA-
selective endothelin antagonism, therefore, remains untested in
these patients, although reduced interest from the pharmaceu-
tical industry in this area means that such trials are unlikely to
be undertaken in the near future. Acute treatment of patients
with CHF with sitaxsentan, a selective ETA blocker, seemed to
have a preferential effect on the pulmonary circulation, without
affecting systemic haemodynamics,44 suggesting that this
approach might be particularly worthwhile for patients with
pulmonary hypertension. Even if the consensus emerges that
endothelin antagonists do not confer benefit in CHF, they are
now licensed for the treatment of pulmonary arterial hyperten-
sion and are being developed for other clinical applications in
chronic renal disease, systemic sclerosis, oncology and the
management of pain. If the pharmaceutical industry acted in a
more open and transparent fashion, allowing full peer review of
past trial outcomes, then valuable lessons might be better
applied to successful developments in these new areas. For all
of these reasons, we would argue that publication is good for
the public health.
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